You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial

Article Text

Article menu

Download PDFPDF

XML
Chronic obstructive pulmonary disease
Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial
  1. Guillaume Prieur1,
  2. Clement Medrinal2,3,
  3. Yann Combret4,5,
  4. Aurora Robledo Quesada6,
  5. Fabrice Prieur7,8,
  6. Jean Quieffin6,
  7. Jean Christian Borel9 and
  8. Gregory Reychler10
  1. 1 Pulmonology Department and Pulmonary Rehabilitation Department, Groupe Hospitalier du Havre, Montivilliers, France
  2. 2 Normandie UnivRouen France Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
  3. 3 Pulmonology Department Groupe Hospitalier du Havre, Montivilliers, France
  4. 4 Physiotherapy Department, Groupe Hospitalier du Havre, Montivilliers, France
  5. 5 Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie Université Catholique de Louvain, 1200 Brussels, Service de Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium
  6. 6 Pulmonology Department, Groupe Hospitalier du Havre, Montivilliers, France
  7. 7 Université Paris Saclay, Orsay Cedex, France
  8. 8 CIAMS Université d’Orléans, Orléans, France
  9. 9 Research and Development, Association AGIR à dom, Grenoble, France
  10. 10 Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Service de Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium
  1. Correspondence to Dr Guillaume Prieur; gprieur.kine{at}gmail.com

Abstract

Introduction Early pulmonary rehabilitation is recommended after a severe exacerbation of chronic obstructive pulmonary disease (COPD). However, this is difficult to implement, particularly for exercise training. High-flow nasal therapy (HFNT) may reduce the work of breathing and dyspnoea and may improve exercise tolerance.

Methods and analysis This is a single-centre, prospective, controlled, randomised, cross-over study. Eligible patients will have a diagnosis of COPD (postbronchodilator forced expiratory volume in 1 s/forced vital capacity ratio of <0.7). Two constant work rate exercise tests at 80% of the peak work rate will be carried out on two consecutive days with and without HFNT. The primary outcome will be the difference in endurance time between the two conditions. Secondary outcomes will be the change in muscle oxygenation during exercise, dyspnoea and muscle fatigue, respiratory muscle strength after exercise, respiratory rate, cardiac frequency, transcutaneous CO2 pressure and pulsed O2 saturation. Nineteen patients will be included. Data will be analysed as intention to treat by a blinded statistician.

Ethics and dissemination Ethics approval has been obtained from the Ethics Committees Nord-Ouest III, Caen, France (N° ID RCB: 2016-A01325-46). The study will begin in April 2017 for a duration of 2 years. The results of the trial will be presented at national and international meetings and published in peer-reviewed journals.

Trial registration number NCT03058081.

  • COPD
  • Exercise
  • High Flow Nasal Therapy
  • muscle oxygenation
  • pulmonary rehabilitation

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjresp-2017-000191

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Trial concept and design: GP, CM, YC, JCB and GR. Acquisition of data: GP, CM, ARQ and YC. Analysis and interpretation of data: GP, GR, FP and JQ. Drafting the article: GP, CM, YC, JCB and GR. Revising it critically for important intellectual content and final approval of the version to be published: all authors. GP had full access to all trial data and takes responsibility for the integrity of the data and the accuracy of the data analysis.

    • Competing interests None declared.

    • Patient consent Protocol study.

    • Ethics approval Ethics Committees Nord-Ouest III, Caen, France.

    • Provenance and peer review Not commissioned; externally peer reviewed.